摘要
目的观察喜普妙与路优泰治疗躯体化抑郁症的临床疗效和脑电图变化。方法选取2015年1月至2017年2月确诊的60例抑郁症患者,随机分为治疗A组(予路优泰),治疗B组(予喜普妙),对照组给予单纯的心理治疗,比较治疗前后汉密尔顿抑郁量表(HAMD)的评分及脑电图变化。结果第12周治疗A组HAMD评分为(10.40±5.86)分、B组为(8.20±5.24)分,较对照组的(23.60±3.57)分明显下降(P<0.01);治疗后,对照组脑电图总异常率为60.00%,高于治疗组的20.00%(P<0.05)。结论喜普妙与路优泰治疗躯体化抑郁症疗效均较好,但喜普妙起效较路优泰更快,同时应用脑电图检查对抑郁症的诊断有一定临床意义。
Objective To observe the clinical efficacy of Cipramil and Neurostan in the treatment of somatization depression and the changes of electroencephalogram（ EEG） before and after treatment. Methods Totally 60 patients with somatization depression from January 2015 to February 2017 were selected and randomly divided into the treatment group A（ group A, treated with Neurostan）, the treatment group B（ group B,treated with Cipramil） and the control group（ treated with simple psychotherapy）. The Hamilton Depression Scales（ HAMD） scores and EEG changes before and after treatment were compared. Results After 12 weeks, The HAMD scores of group A and group B were（10. 40 ± 5. 86） points and（8. 20 ± 5. 24） points,respectively,which were significantly lower than（23. 60 ± 3. 57）points in the control group（ P〈0. 01）. After treatment, the abnormal rate of EEG in control group was 65. 00%, which was significantly higher than 25. 00% in the treatment group（ P〈0. 01）. Conclusion Both of Cipramil and Neurostan in the treatment of somatization depression have good effect,but compared with Neurostan,Cipramil works faster,at the same time the application of EEG examination in the diagnosis of depression has certain clinical significance.
出处
《中国药业》
CAS
2017年第21期39-41,共3页
China Pharmaceuticals
基金
河北省卫生计生委"河北省2017年度医学科学研究重点课题计划(唐山部分)"[20171391]
关键词
抑郁症
喜普妙
路优泰
脑电图
depression
Cipramil
Neurostan
electroencephalogram
